Infectious Disease Control

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...

2022-11-23 19:43 4338

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease ar...

2022-11-21 18:56 4785

Manulife Hong Kong expands partnership with Christian Family Service Centre to support long COVID recovery in underserved communities

New program to provide comprehensive healthcare services to empower sustained health and better wellbeing HONG KONG, Nov. 17, 2022 /PRNewswire/ -- Manulife Hong Kong today announced the launch of "Manulife Health Voucher Program – COVID Recovery" (hereafter referred to as the "Program") in partn...

2022-11-17 14:22 3062

BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...

2022-11-16 21:00 5091

Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022

XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipmen...

2022-11-15 21:19 3361

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

* The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary * Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains * The trial showed no benefit for a bivalent vaccin...

2022-11-08 21:00 4668

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...

2022-11-02 08:10 3063

GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis

SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supportedChulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production a...

2022-11-01 11:39 4935

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

GAITHERSBURG, Md., Oct. 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received eme...

2022-10-22 03:25 8543

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...

2022-10-19 20:00 3072

The Grand Hamdan Award goes to two scientists in Australia

DUBAI, UAE, Oct. 19, 2022 /PRNewswire/ -- According to an official announcement made recently inDubai, Prof. Ian Hector Frazer and the Late Dr. Jian Zhou are the winners of the Grand Hamdan Award for the topic of – Infectious Diseases in the Award's 12th term (2021-2022).

2022-10-19 04:05 2016

GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) - the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new products.

SINGAPORE, Oct. 17, 2022 /PRNewswire/ -- GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a private corporation based inBangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP™ which contains human...

2022-10-17 23:56 5973

World Health Summit kicks off with German Chancellor Scholz, numerous Government Officials, WHO Director-General Tedros

Global health in focus BERLIN, Oct. 17, 2022 /PRNewswire/ -- The World Health Summit 2022, the world's leading meeting for global health, began on Sunday morning inBerlin. For the first time it is co-hosted by the World Health Organization (WHO). Among the central topics are climate change and h...

2022-10-17 10:24 1534

With New Commitment, Gates Foundation Joins Call to Help End Polio

BERLIN, Oct. 17, 2022 /PRNewswire/ -- Today at the World Health Summit, the Bill & Melinda Gates Foundation announced it will commit$1.2 billion to support efforts to end all forms of polio globally. The announcement was made ahead of a key pledging moment that will be co-hosted by Germany and the...

2022-10-17 01:30 2805

Gilead and the IAS start second year of partnership to honor champions of stigma-free HIV care services in Asia and Latin America

SINGAPORE, Oct. 13, 2022 /PRNewswire/ -- Gilead Sciences, Inc. and IAS – the International AIDS Society – have renewed their Me and My Healthcare Provider partnership to expand the campaign inBrazil, Hong Kong, Mexico, South Korea and Taiwan. The collaborative partnership, now entering its second...

2022-10-13 11:10 2636

Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

* Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 * Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating the consist...

2022-10-12 21:35 3286

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects * Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people wit...

2022-09-26 20:00 3211

Gates Foundation Announces $1.27 Billion in Health and Development Commitments to Advance Progress Toward the Global Goals

First in-person Goalkeepers event since 2019 convenes global changemakers to highlight the urgency of achieving a more equitable world by 2030 NEW YORK, Sept. 22, 2022 /PRNewswire/ -- During United Nations General Assembly week, the Bill & Melinda Gates Foundation—alongside governments, philanth...

2022-09-22 06:36 2597

MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19

LONDON, Sept. 21, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Lo...

2022-09-21 17:13 3624

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

* Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections inChina * The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and market...

2022-09-20 17:00 3584
1 ... 78910111213 ... 34

Week's Top Stories